Brief: Newbury Pharmaceuticals Secures Generic Approval For Buspiron
Oct 28 (Reuters) - Newbury Pharmaceuticals AB
NEWBRY.ST :
* NEWBURY PHARMACEUTICALS SECURES GENERIC APPROVAL FOR
BUSPIRON
* NEWBURY PHARMACEUTICALS AB - WILL PROCEED TO LAUNCH
PRODUCT
* NEWBURY PHARMACEUTICALS AB - ANNUAL VALUE OF MARKET
ESTIMATED TO
BE 0,9 MEUR ACCORDING TO DLMI NORDIC PHARMA INSIGHTS
Source text: ID:nMFN8Hl1Ps
Further company coverage: NEWBRY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newbury Pharmaceuticals AB
See all newsBrief: Newbury Secures Hospital Portfolio Rights In Iraq
Brief: Newbury Signs Licence And Supply Deal For Guanfacine
Brief: Newbury Pharmaceuticals Gets Approval for Tofacitinib Newbury
Brief: Newbury Pharmaceuticals Secures Generic Approval For Dalbavancin Newbury
Brief: Newbury Pharmaceuticals Reports Q3 EBITDA Of SEK -4 Mln